で公開中です！ 詳しく見る
ADMAのアイコン

ADMA Biologics
ADMA

10.68 USD
-0.05
0.47%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
10.68
0.00
0%
1日
-0.47%
5日間
3.49%
1か月
20%
3か月
21.23%
6か月
-0.56%
年初来
-40.27%
1年
-26.65%
5年間
870.91%
10年間
68.72%
 

概要： ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

従業員数： 647

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 2.6%
ニュートラル 95.4%
ネガティブ 2.1%
ニュートラル
GlobeNewsWire
昨日
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
ポジティブ
Zacks Investment Research
4 日前
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
ニュートラル
Zacks Investment Research
8 日前
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
ポジティブ
Zacks Investment Research
8 日前
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
ネガティブ
Zacks Investment Research
17 日前
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
ニュートラル
Zacks Investment Research
22 日前
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
ポジティブ
Zacks Investment Research
22 日前
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
ポジティブ
Zacks Investment Research
28 日前
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
ニュートラル
Newsfile Corp
先月
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
ネガティブ
Zacks Investment Research
先月
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています